Highland Private Wealth Management purchased a new stake in Becton Dickinson and Co (NYSE:BDX) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 870 shares of the medical instruments supplier’s stock, valued at approximately $217,000.
A number of other hedge funds also recently bought and sold shares of BDX. Marshall Wace LLP acquired a new stake in shares of Becton Dickinson and during the third quarter worth about $953,000. Vanguard Group Inc boosted its stake in shares of Becton Dickinson and by 1.3% during the third quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock worth $5,654,895,000 after buying an additional 283,433 shares during the period. Fox Run Management L.L.C. boosted its stake in shares of Becton Dickinson and by 135.4% during the fourth quarter. Fox Run Management L.L.C. now owns 2,267 shares of the medical instruments supplier’s stock worth $511,000 after buying an additional 1,304 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in shares of Becton Dickinson and by 86.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 33,272 shares of the medical instruments supplier’s stock worth $7,496,000 after buying an additional 15,382 shares during the period. Finally, Windsor Group LTD boosted its stake in shares of Becton Dickinson and by 21.7% during the fourth quarter. Windsor Group LTD now owns 2,286 shares of the medical instruments supplier’s stock worth $515,000 after buying an additional 407 shares during the period. 85.24% of the stock is owned by institutional investors and hedge funds.
In other Becton Dickinson and news, EVP Betty D. Larson sold 1,700 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $224.97, for a total value of $382,449.00. Following the completion of the transaction, the executive vice president now directly owns 11,493 shares of the company’s stock, valued at $2,585,580.21. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Ribo Alberto Mas sold 2,104 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $255.00, for a total transaction of $536,520.00. Following the completion of the transaction, the executive vice president now directly owns 19,074 shares of the company’s stock, valued at $4,863,870. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,384 shares of company stock valued at $7,901,023. 0.12% of the stock is currently owned by corporate insiders.
Shares of NYSE:BDX opened at $225.62 on Thursday. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.59. The stock has a market capitalization of $60.36 billion, a P/E ratio of 20.49, a PEG ratio of 1.68 and a beta of 1.16. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $265.87.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 EPS for the quarter, beating the Zacks’ consensus estimate of $2.57 by $0.02. The firm had revenue of $4.20 billion during the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The firm’s revenue was down .6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.65 earnings per share. On average, sell-side analysts anticipate that Becton Dickinson and Co will post 11.69 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 7th will be given a $0.77 dividend. The ex-dividend date is Thursday, June 6th. This represents a $3.08 dividend on an annualized basis and a yield of 1.37%. Becton Dickinson and’s payout ratio is currently 27.97%.
BDX has been the subject of several recent research reports. Piper Jaffray Companies increased their target price on shares of Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 5th. Zacks Investment Research downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Wednesday, February 6th. TheStreet upgraded shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Raymond James decreased their target price on shares of Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a research note on Tuesday, March 19th. Finally, ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $255.31.
COPYRIGHT VIOLATION WARNING: “Highland Private Wealth Management Purchases Shares of 870 Becton Dickinson and Co (BDX)” was published by Zolmax and is the sole property of of Zolmax. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://zolmax.com/investing/highland-private-wealth-management-purchases-shares-of-870-becton-dickinson-and-co-bdx/3085782.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.